Works about NILOTINIB
Results: 538
Influence of Neutralization Precipitation Conditions on the Physical Stability of Amorphous Solid Pharmaceuticals.
- Published in:
- Molecules, 2025, v. 30, n. 4, p. 764, doi. 10.3390/molecules30040764
- By:
- Publication type:
- Article
New-generation tyrosine kinase inhibitor-associated asymptomatic cerebrovascular stenosis: two illustrative cases.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Crystal Structure of Nilotinib Hydrochloride Monohydrate According to Powder X-Ray Diffraction Data.
- Published in:
- Journal of Structural Chemistry, 2024, v. 65, n. 3, p. 585, doi. 10.1134/S0022476624030132
- By:
- Publication type:
- Article
Nilotinib effect on hepatic and renal functions in a sample of Iraqi patients with chronic myeloid leukemia.
- Published in:
- Iraqi Journal of Cancer & Medical Genetics, 2017, v. 10, n. 1, p. 21
- By:
- Publication type:
- Article
Synthesis, molecular modeling, and biological evaluation of novel imatinib derivatives as anticancer agents.
- Published in:
- Turkish Journal of Chemistry, 2022, v. 46, n. 1, p. 86, doi. 10.3906/kim-2107-23
- By:
- Publication type:
- Article
Overcoming the imatinib-resistant BCR-ABL mutants with new ureidobenzothiazole chemotypes endowed with potent and broad-spectrum anticancer activity.
- Published in:
- Journal of Enzyme Inhibition & Medicinal Chemistry, 2023, v. 38, n. 1, p. 1, doi. 10.1080/14756366.2023.2189097
- By:
- Publication type:
- Article
CNS demyelination associated with nilotinib.
- Published in:
- Neurological Sciences, 2023, v. 44, n. 9, p. 3335, doi. 10.1007/s10072-023-06827-4
- By:
- Publication type:
- Article
Surgical resection of recurrent gastrointestinal stromal tumor after interruption of long-term nilotinib therapy.
- Published in:
- Surgical Case Reports, 2016, v. 2, n. 1, p. 1, doi. 10.1186/s40792-016-0266-y
- By:
- Publication type:
- Article
Oral Implant Treatment for a Patient Undergoing Molecularly Targeted Drug Therapy for Chronic Myelocytic Leukemia: A Case Report.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Quality of life among chronic myeloid leukemia patients in the second-line treatment with nilotinib and influential factors.
- Published in:
- Quality of Life Research, 2022, v. 31, n. 3, p. 733, doi. 10.1007/s11136-021-02952-9
- By:
- Publication type:
- Article
Nilotinib Yields Better Rates of Molecular Response Than Imatinib in the Frontline Setting.
- Published in:
- Personalized Medicine in Oncology, 2016, v. 5, n. 1, p. 38
- Publication type:
- Article
Highlights from EHA 2013.
- Published in:
- 2013
- Publication type:
- Proceeding
The Potential Safe Antifibrotic Effect of Stem Cell Conditioned Medium and Nilotinib Combined Therapy by Selective Elimination of Rat Activated HSCs.
- Published in:
- BioMed Research International, 2021, p. 1, doi. 10.1155/2021/6678913
- By:
- Publication type:
- Article
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00917-4
- By:
- Publication type:
- Article
Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00891-x
- By:
- Publication type:
- Article
Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Activated naïve γδ T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia.
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 11, p. 1, doi. 10.1038/s41408-021-00572-7
- By:
- Publication type:
- Article
Lysosomal Fusion: An Efficient Mechanism Increasing Their Sequestration Capacity for Weak Base Drugs without Apparent Lysosomal Biogenesis.
- Published in:
- Biomolecules (2218-273X), 2020, v. 10, n. 1, p. 1, doi. 10.3390/biom10010077
- By:
- Publication type:
- Article
The Lysosomal Sequestration of Tyrosine Kinase Inhibitors and Drug Resistance.
- Published in:
- Biomolecules (2218-273X), 2019, v. 9, n. 11, p. 675, doi. 10.3390/biom9110675
- By:
- Publication type:
- Article
Chronic Myeloid Leukemia Patient's Voice About the Experience of Treatment-Free Remission Failure: Results From the Italian Sub-Study of ENESTPath Exploring the Emotional Experience of Patients During Different Phases of a Clinical Trial.
- Published in:
- Frontiers in Psychology, 2019, p. N.PAG, doi. 10.3389/fpsyg.2019.00329
- By:
- Publication type:
- Article
BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia.
- Published in:
- Frontiers in Oncology, 2019, p. 1, doi. 10.3389/fonc.2019.00939
- By:
- Publication type:
- Article
Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00372
- By:
- Publication type:
- Article
Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00188
- By:
- Publication type:
- Article
Ameliorative Effects of Nilotinib on CCl4 Induced Liver Fibrosis V Attenuation of RAGE/HMGB1 Gene Expression and Oxidative Stress in Rat.
- Published in:
- Chonnam Medical Journal, 2017, v. 53, n. 2, p. 118, doi. 10.4068/cmj.2017.53.2.118
- By:
- Publication type:
- Article
Computer-aided peptide-based drug design for inositol-requiring enzyme 1.
- Published in:
- Basic & Clinical Cancer Research, 2022, v. 14, n. 4, p. 1
- By:
- Publication type:
- Article
Examination of ototoxicity induced by imatinib, being a tyrosine kinase inhibitor: An experimental study.
- Published in:
- Indian Journal of Otology, 2020, v. 26, n. 3, p. 141, doi. 10.4103/indianjotol.INDIANJOTOL_129_20
- By:
- Publication type:
- Article
Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation.
- Published in:
- Skeletal Muscle, 2018, v. 8, p. 1, doi. 10.1186/s13395-018-0150-5
- By:
- Publication type:
- Article
Therapeutic drug monitoring of imatinib in patients of chronic myeloid leukemia – Chronic phase.
- Published in:
- Journal of Pharmacology & Pharmacotherapeutics, 2021, v. 12, n. 2, p. 61, doi. 10.4103/jpp.jpp_28_21
- By:
- Publication type:
- Article
Investigating the potential therapeutic role of targeting STAT3 for overcoming drug resistance by regulating energy metabolism in chronic myeloid leukemia cells.
- Published in:
- Iranian Journal of Basic Medical Sciences, 2022, v. 25, n. 7, p. 904, doi. 10.22038/IJBMS.2022.64138.14121
- By:
- Publication type:
- Article
Treatment-Free Remission After Second-Line Nilotinib Treatment.
- Published in:
- 2018
- By:
- Publication type:
- Letter
Treatment-Free Remission After Second-Line Nilotinib Treatment.
- Published in:
- 2018
- By:
- Publication type:
- Letter
Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy.
- Published in:
- 2018
- By:
- Publication type:
- Letter
Examining the Early Period Effect of Nilotinib on Hearing: An Experimental Study.
- Published in:
- Journal of International Advanced Otology, 2020, v. 16, n. 2, p. 77, doi. 10.5152/iao.2019.5908
- By:
- Publication type:
- Article
Examining the Early Period Effect of Nilotinib on Hearing: An Experimental Study.
- Published in:
- Journal of International Advanced Otology, 2020, v. 16, n. 1, p. 77, doi. 10.5152/iao.2019.5908
- By:
- Publication type:
- Article
Tyrosine Kinase Inhibitors in the Clinical Setting: A Conundrum of Choices.
- Published in:
- 2020
- By:
- Publication type:
- Editorial
Systematic Review and Meta-Analysis of -New-Generation Tyrosine Kinase Inhibitors versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia.
- Published in:
- Acta Haematologica, 2020, v. 143, n. 3, p. 204, doi. 10.1159/000501537
- By:
- Publication type:
- Article
BCR-ABL1 Transcript Levels at 3 and 6 Months Are Better for Identifying Chronic Myeloid Leukemia Patients with Poor Outcome in Response to Second-Line Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure: A Report from a Single Institution.
- Published in:
- Acta Haematologica, 2015, v. 134, n. 4, p. 248, doi. 10.1159/000430835
- By:
- Publication type:
- Article
BCR-ABL1 Acute Myeloid Leukemia: Clonal Selection of a BCR-ABL1<sup>-</sup> Subclone as a Cause of Refractory Disease with Nilotinib Treatment.
- Published in:
- Acta Haematologica, 2015, v. 133, n. 2, p. 237, doi. 10.1159/000368176
- By:
- Publication type:
- Article
Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia.
- Published in:
- PLoS ONE, 2019, v. 14, n. 12, p. N.PAG, doi. 10.1371/journal.pone.0226552
- By:
- Publication type:
- Article
Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma.
- Published in:
- PLoS ONE, 2019, v. 14, n. 9, p. 1, doi. 10.1371/journal.pone.0214901
- By:
- Publication type:
- Article
Prevalence and determinants of non-adherence to Imatinib in the first 3-months treatment among newly diagnosed Ethiopian’s with chronic myeloid leukemia.
- Published in:
- PLoS ONE, 2019, v. 14, n. 3, p. 1, doi. 10.1371/journal.pone.0213557
- By:
- Publication type:
- Article
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 2, p. 427, doi. 10.1007/s00277-023-05556-0
- By:
- Publication type:
- Article
Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 6, p. 1395, doi. 10.1007/s00277-023-05199-1
- By:
- Publication type:
- Article
Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials.
- Published in:
- Annals of Hematology, 2023, v. 102, n. 6, p. 1375, doi. 10.1007/s00277-023-05159-9
- By:
- Publication type:
- Article
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.
- Published in:
- Annals of Hematology, 2021, v. 100, n. 8, p. 2005, doi. 10.1007/s00277-020-04392-w
- By:
- Publication type:
- Article
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Assessment of chronic renal injury in patients with chronic myeloid leukemia in the chronic phase receiving tyrosine kinase inhibitors.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement.
- Published in:
- 2015
- By:
- Publication type:
- Letter